Sign in

1801 on Hong Kong Stock Exchange

Innovent Biologics

Chinese Biopharmaceutical Company

Innovent Biologics, Inc. (Innovent; Chinese: 信达生物制药; pinyin: Xìndá shēngwù zhìyào) is a publicly listed Chinese biopharmaceutical company that is headquartered in Suzhou, Jiangsu.2 Its shares trade on Hong Kong Stock Exchange under the symbol 1801.1 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

Apr 28, 2011Founded1

Compare with another stock.

  • Ticker1801 on Hong Kong Stock Exchange1
  • HeadquartersSuzhou1
  • Websitewww.innoventbio.com
  • Legal formcompany limited by shares3
  • LEI25490058ONL9SCIE1R223
  • StatusActive3
  • LEI statusLapsed (not renewed)3
  • Registered addressc/o Maricorp Services Ltd., KY1-1105 Grand Cayman, Cayman Islands3
  • Registered withGeneral Registry, CL-2555093

See how the biggest companies compare on our leaderboards

Gate 1 of Innovent Biologics-20221117
Photo: Shwangtianyuan, CC BY-SA 4.0, via Wikimedia Commons5

Innovent Biologics, Inc. (Innovent; Chinese: 信达生物制药; pinyin: Xìndá shēngwù zhìyào) is a publicly listed Chinese biopharmaceutical company that is headquartered in Suzhou, Jiangsu.2

The story

Innovent was founded in 2011 by Yu Dechao to focus on the development of a class of biotech drugs known as monoclonal antibodies. It received venture capital funding from Eli Lilly and Company and Fidelity Investments. Other investors included China Life, Hillhouse Capital and Temasek.

In March 2015, Innovent and Eli Lilly agreed to a deal that would pay $56 million upfront to Innovent to co-develop at least three experimental cancer drugs. Innovent would be paid more than $400 million if one of the Innovent drugs hit certain development and commercial goals.

In October 2018, Innovent held its initial public offering and became a listed company on the Hong Kong Stock Exchange. The offering raised $421 million.

In December 2018, Innovent's Sintilimab was approved in China. In 2020, Eli Lilly paid $200 million upfront and committed up to $825 million to gain ex-China rights to it. However, in December 2022, Eli Lilly terminated the deal due to Food and Drug Administration rejection.

In June 2025, Innovent's Mazdutide was approved in China. It was the first Chinese company to win regulatory approval to sell a GLP-1 drug for weight loss and diabetes. It partnered with JD Health to help distribute the drug.

In August 2025, Sanofi stated it would invest $307.88 million in Innovent to jointly develop two cancer drugs in China.

In October 2025, Takeda Pharmaceutical Company signed an $11.4 billion deal with Innovent to help accelerate the development of immuno-oncology and antibody-drug conjugate cancer therapies. The deal includes a $1.2 billion upfront payment from Takeda.

In November 2025, it was announced that Innovent would become a member of the Hang Seng Index.

From Wikipedia’s article on Innovent Biologics, shared under CC BY-SA 4.0.4

Timeline

  1. Apr 28, 2011Founded Founded1

Calendar

Drug trials and FDA: coming up

  1. Dec 30, 2026Phase 3 trial readout expected Phase 3 trial of Irinotecan OR Paclitaxel or Trifluridine/tipiracil（ FTD/TPI） and IBI343 in Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma: primary completion expected Dec 30, 2026 (ClinicalTrials.gov NCT06238843).6
  2. Dec 31, 2026Phase 3 trial readout expected Phase 3 trial of IBI362 and semaglutide in Overweight: primary completion expected Dec 31, 2026 (ClinicalTrials.gov NCT06884293).7
  3. Dec 31, 2026Phase 3 trial readout expected Phase 3 trial of IBI311 in Thyroid Eye Disease: primary completion expected Dec 31, 2026 (ClinicalTrials.gov NCT07113262).8
  4. Feb 28, 2027Phase 3 trial readout expected Phase 3 trial of Aflibercept Ophthalmic and IBI302 in Neovascular Age-related Macular Degeneration: primary completion expected Feb 28, 2027 (ClinicalTrials.gov NCT05972473).9
  5. Apr 30, 2027Phase 3 trial readout expected Phase 3 trial of Febuxostat and Tigulixostat in Gout: primary completion expected Apr 30, 2027 (ClinicalTrials.gov NCT07414394).10
  6. May 7, 2027Phase 3 trial readout expected Phase 3 trial of IBI362 in Sleep Apnea: primary completion expected May 7, 2027 (ClinicalTrials.gov NCT06931028).11

Drug trials and FDA: recently

  1. Sep 23, 2026Phase 2 trial completed Phase 2 trial of IBI362 in Metabolic Dysfunction-associated Steatohepatitis (MASH): primary completion Sep 23, 2026, no results posted yet (ClinicalTrials.gov NCT06937749).12
  2. Dec 31, 2025Phase 3 trial completed Phase 3 trial of IBI310, Sintilimab and others in Hepatocellular Carcinoma: primary completion Dec 31, 2025, no results posted yet (ClinicalTrials.gov NCT04720716).13

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13